Dominantly Inherited Alzheimer Network (DIAN)

  • STATUS
    Recruiting
  • End date
    Jul 23, 2024
  • participants needed
    700
  • sponsor
    Washington University School of Medicine
Updated on 20 June 2021
Investigator
Hisako Fujii, PhD
Primary Contact
Osaka City University (6.1 mi away) Contact
+20 other location
cognitive impairment

Summary

The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

Description

Dominantly inherited Alzheimer's disease (AD) represents less than 1% of all cases of AD and is an important model for study because the responsible mutations have known biochemical consequences that are believed to underlie the pathological basis of the disorder. Three major hypotheses will be tested:

  • First, that there is a period of preclinical (presymptomatic) AD in individuals who are destined to develop early-onset dementia (gene carriers) that can be detected by changes in biological fluids and in neuroimaging correlates in comparison with individuals who will not develop early-onset dementia (non-carriers).
  • Second, because all identified causative mutations for AD affect the normal processing of amyloid precursor protein (APP) and increase brain levels of amyloid-beta 42 (A42), the sequence of preclinical changes initially will involve A42 (production and clearance; reduced levels in cerebrospinal fluid [CSF]), followed by evidence for cerebral deposition of A42 (amyloid imaging), followed by cerebral metabolic activity (functional imaging), and finally by regional atrophy (structural imaging).
  • Finally, that the phenotype of symptomatic early-onset familial AD, including its clinical course, is similar to that of late-onset "sporadic" AD.

The following specific aims will be used to test these hypotheses:

  1. Maintain the established international DIAN registry of individuals (mutation carriers and non-carriers; pre-symptomatic and symptomatic) who are biological adult children of a parent with a known causative mutation for AD in the APP, PSEN1, or PSEN2 genes and assess participants every 2 years with the uniform DIAN protocol.
  2. Maintain the integrated DIAN database and biospecimen repository to disseminate data and tissue to qualified investigators (within and outside of DIAN) in a user-friendly manner and to permit analyses within, between, and among the various data domains that will
    include
  3. In asymptomatic mutation carriers (using non-carriers as controls), determine the temporal ordering and rate of intraindividual change in clinical, cognitive, behavioral, imaging, and fluid biomarkers of AD prior to estimated age of symptom onset.
  4. In symptomatic mutation carriers, compare the clinical and neuropathological phenotypes of ADAD to those of LOAD, using datasets such as ADNI.
  5. Utilize the DIAN cohort and its database and biospecimen repository to support new scientific studies, including use of exome chip technology to examine potential modifiers of age at symptomatic onset, exploratory investigation of new biomarker analytes, imaging modalities and techniques, perform exploratory genetic analysis to test whether novel AD genes identified through GWAS and sequencing of late onset AD cases also influence variation in age at onset of changes in biomarker endophenotypes in FAD kindred, and generate genome-wide DNA methylation data for pilot study and perform exploratory analyses to look for changes in DNA methylation in longitudinal samples from DIAN participants.
  6. Provide genetic counseling to any and all DIAN participants who wish to learn their mutation status and, for those who decide to learn their status after counseling, provide genetic testing by Clinical Laboratory Improvement Amendments (CLIA) - approved laboratories (i.e., outside of DIAN).

Details
Condition Dementia, Alzheimer's Disease, alzheimer, dementia alzheimer's type
Clinical Study IdentifierNCT00869817
SponsorWashington University School of Medicine
Last Modified on20 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Written informed consent obtained from participant and collateral source prior to any study-related procedures
Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD
Cognitively normal. Primary enrollment will focus on recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with very mild, mild, or moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center
Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study
Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade level (international equivalent) or above

Exclusion Criteria

Under age 18
Medical or psychiatric illness that would interfere in completing initial and follow-up visits
Requires nursing home level care
Has no one who can serve as a study informant
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note